New York, November 23, 2015 -- Pfizer's acquisition of Allergan will improve the company's scale, diversity and research pipeline, but will also increase shareholder payouts, lowering the company's cash levels over time, says Moody's Investors Service.
Vollständigen Artikel bei Moodys lesen